Your browser doesn't support javascript.
loading
Efficacy and safety of hymenoptera venom immunotherapy.
Kayikci, Hazal; Bostan, Ozge Can; Tuncay, Gulseren; Cihanbeylerden, Melek; Damadoglu, Ebru; Karakaya, Gul; Kalyoncu, Ali Fuat.
Afiliação
  • Kayikci H; From the Division of Allergy and Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey, and.
  • Bostan OC; Division of Allergy and Clinical Immunology, Adiyaman Education and Training Hospital, Faculty of Medicine, Adiyaman, Turkey.
  • Tuncay G; From the Division of Allergy and Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey, and.
  • Cihanbeylerden M; From the Division of Allergy and Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey, and.
  • Damadoglu E; From the Division of Allergy and Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey, and.
  • Karakaya G; From the Division of Allergy and Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey, and.
  • Kalyoncu AF; From the Division of Allergy and Immunology, Department of Chest Diseases, Hacettepe University School of Medicine, Ankara, Turkey, and.
Allergy Asthma Proc ; 45(4): 268-275, 2024 Jul 01.
Article em En | MEDLINE | ID: mdl-38982604
ABSTRACT

Background:

Being stung by Hymenoptera species can cause life-threatening anaphylaxis. Although venom immunotherapy (VIT) seems to be the most effective treatment, its long-term efficacy, and risk factors for adverse events remain unclear.

Objective:

The objective was to investigate the long-term efficacy of VIT and evaluate adverse events and risk factors related to this.

Method:

Patients who received VIT in a tertiary-care adult allergy clinic between January 2005 and July 2022 were included. Patients' data were compared with those of individuals who had been diagnosed with bee and/or wasp venom allergy during the same period but had not received VIT and experienced field re-stings.

Results:

The study included 105 patients with venom allergy, of whom 68 received VIT and 37 did not receive VIT. Twenty-three patients (34%) completed 5 years of VIT, and the overall mean ± standard deviation VIT duration was 46.9 ± 20.9 months. Re-stings occurred in 5 of 23 patients who completed 5 years of VIT, and none of them developed a systemic reaction. Eighteen patients (40%) experienced re-stings after prematurely discontinuing VIT, of whom eight (44%) developed a systemic reaction. In the control group of patients who did not receive VIT, 26 patients (70.3%) experienced re-stings, and all had systemic reactions (100%), with no change in their median Mueller scores. There was a significant difference in the median Mueller score change between the patients who received VIT and the controls who did not (p = 0.016). A total of 13 patients (19%) experienced adverse events while receiving VIT, which were systemic reactions in nine honeybee VIT. The use of ß-blockers was determined as the most important risk factor (odds ratio 15.9 [95% confidence interval, 1.2-208.8]; p = 0.035).

Conclusion:

It was confirmed that VIT was effective in both reducing the incidence and the severity of re-sting reactions. These effects were more pronounced in the patients who completed 5 years of VIT.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Venenos de Abelha / Dessensibilização Imunológica / Himenópteros / Anafilaxia / Mordeduras e Picadas de Insetos Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Venenos de Abelha / Dessensibilização Imunológica / Himenópteros / Anafilaxia / Mordeduras e Picadas de Insetos Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article